ClinicalTrials.gg
TerminatedNCT06643117LotusUpdated Jun 26, 2025

Similar Efficacy, Safety, and Immunogenicity of FYB206 in Comparison to Keytruda as add-on to Chemotherapy in Patients With Non-squamous Non-small Cell Lung Cancer (NSCLC)

A Phase 3 interventional study of FYB206 and FYB206 in Non Small Cell Lung Cancer and Non-Squamous Non-Small Cell Lung Cancer, sponsored by Formycon AG. Terminated at 13 sites in 3 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-06-26.

Sponsored by Formycon AG · Phase 3, Interventional, and Treatment

How we know · 7 judgments

Why this study was terminated
Formycon concluded that continuing the trial is no longer necessary for the development and approval of FYB206. The therapeutic comparability of FYB206 to Keytruda can be demonstrated based on comprehensive analytical and PK comparability data

From the registry’s dates

  • Primary completion was May 2025, 1 year 6 months ago, and no results have been posted to the registry.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
25
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 115 studies in Carcinoma, Non-Small-Cell Lung with a site in Malaysia — 19 open to participants now, 55 under way, 36 of them phase 3. Carcinoma, Non-Small-Cell Lung · Malaysia.

Enrollment
105th of 111
25 · median 393
Started
2024
with 15 others
Phase 3
69 of 115
12 open now
Registered
100th of 115
by date

Among the 115 studies in Carcinoma, Non-Small-Cell Lung with a site in Malaysia, this one is the 105th largest by enrollment of the 111 interventional ones that give a count, is one of 16 that started in 2024, is one of 69 in phase 3, and was the 100th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

19 of the 115 studies in Carcinoma, Non-Small-Cell Lung with a site in Malaysia are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in Malaysia have not opened yet or have stopped. Only those recruiting at a site in Malaysia →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 115 studies in Carcinoma, Non-Small-Cell Lung with a site in Malaysia, or all of them as a file.
02

Study summary

NSCLC is the most common type of lung cancer. Metastatic cancers are cancers that start to spread to other parts of the body. NSCLC is treated by radiation therapy, with medicines, surgery, or immunotherapy. Immunotherapy is a type of treatment that helps the immune system fight cancer.

The immune system helps the body fight infections and disease. Pembrolizumab is an anti-cancer therapy that works with the immune system to fight cancer cells. Some cancer cells develop a way to hide from the body's immune system and, thus, allow the cancer cells to spread and grow. Pembrolizumab helps the immune system recognize and kill these cancer cells that want to hide. Pembrolizumab is a biologic drug (produced by living organisms) available in the market under the brand name Keytruda. Keytruda is approved globally for the treatment of a variety of cancers and as an addon or after therapy to primary cancer treatment like surgery. This helps prevent the cancer from returning, improving overall survival.

FYB206 is a proposed biosimilar to Keytruda. A biosimilar is not identical, but very similar to its original biologic. Biosimilars are expected to have a similar effect and safety to the original biologic. This clinical trial is intended to demonstrate the comparable effectiveness and safety of FYB206 to Keytruda as an add-on treatment to chemotherapy in patients with metastatic NSCLC who have not received previous anti-cancer treatment that is given directly into the blood.

03

Conditions studied

  • Non Small Cell Lung Cancer
  • Non-Squamous Non-Small Cell Lung Cancer

Keywords

  • pembrolizumab
  • biosimilar
  • lung cancer
  • NSCLC
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed or cytologically confirmed diagnosis of Stage IV non-squamous NSCLC.
  • Confirmation that epidermal growth factor receptor (EGFR) or anaplastic lymphoma kinase (ALK)-directed therapy is not indicated (ie, documentation of absence of tumor-activating/sensitizing EGFR mutations AND absence of ALK gene rearrangements).
  • No prior systemic treatment for non-squamous NSCLC. Patients who received or neoadjuvant therapy are eligible if the adjuvant/neoadjuvant therapy was completed at least 12 months prior to the development of metastatic disease.
  • (ECOG) performance status of 0 or 1.

Exclusion criteria

Exclusion Criteria:

  • Small cell lung cancer (SCLC) or combination of SCLC and NSCLC. Squamous cell tumors and mixed adenosquamous carcinomas of predominantly squamous nature.
  • Known one of the mutations listed below:

    • ROS1 fusion gene
    • BRAF-V600E
    • RET fusion
    • MET Exon 14
  • Known active central nervous system and/or carcinomatous meningitis. Patients with previously treated may participate provided they are clinically stable for at least 2 weeks and have no evidence of new or enlarging brain metastases and are also off 3 days prior to dosing with trial treatment. Stable brain metastases by this definition should be established prior to the first dose of trial treatment. Patients with known untreated, asymptomatic brain metastases (ie, no neurological symptoms, no requirements for corticosteroids, no or minimal surrounding edema, and no lesion >1.5 cm) may participate but will require regular imaging of the brain as a site of disease.
  • Prior treatment with any anti-programmed cell death 1, , or programmed cell death ligand 2 agent or an antibody targeting other immuno-regulatory receptors or mechanisms. Examples of such antibodies include (but are not limited to) antibodies against indoleamine 2, 3-dioxygenase, PD-L1, interleukin 2 receptor, or glucocorticoid-induced tumor necrosis factor receptor-related protein.
Terms in these criteria, in plain language(7)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Adjuvant and neoadjuvant

Neoadjuvant treatment is given before the main treatment (usually surgery), often to shrink a tumor. Adjuvant treatment is given after it, to lower the chance of the cancer coming back.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Brain metastases

Cancer deposits in the brain from a cancer that started elsewhere in the body (CNS metastases include the spinal cord).

Studies differ: some leave out any brain metastases, some accept ones treated and stable for some weeks. Check what this study allows.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Investigator, Outcomes assessor)
Enrollment
25 participants (actual)

Study arms

  • Experimental
    FYB206

    Biological: FYB206

  • Active comparator
    Keytruda

    Biological: Keytruda

Interventions

  • BiologicalFYB206

    FYB206 (Keytruda biosimilar candidate - test product) 200 mg administered as an IV infusion over 30 minutes on Day 1 of each cycle combined with chemotherapy in the first year (treatment Cycles 1 to 17)

  • BiologicalFYB206

    Open-label treatment with FYB206 combined with chemotherapy (Cycles 18-34) to assure treatment continuation for trial patients up to a total of 2 years (a total of 34 treatment cycles)

  • BiologicalPembrolizumabStudies of PembrolizumabPembrolizumab pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Keytruda (reference product) 200 mg administered as an IV infusion over 30 minutes on Day 1 of each cycle combined with chemotherapy in the first year (treatment Cycles 1 to 17)

06

What researchers measure

Primary outcomes

  1. Best objective response rate

    Best objective response rate (bORR): proportion of patients who had a best response of complete response (CR) or partial response (PR) as assessed by blinded independent central review (BICR) per Response Evaluation Criteria in Solid Tumors (RECIST) Version (v) 1.1

    Time frame: 40 Weeks

07

Study locations

13 sites
  • Formycon Investigative Site
    Batumi, Georgia
  • Formycon Investigative Site
    Kutaisi, Georgia
  • Formycon Investigative Site
    Tbilisi, Georgia
  • Formycon Investigative Site
    George Town, Malaysia
  • Formycon Investigative Site
    Kuala Lumpur, Malaysia
  • Formycon Investigative Site
    Kuching, Malaysia
  • Formycon Investigative Site
    Shah Alam, Malaysia
  • Formycon Investigative Site
    Subang Jaya, Malaysia
  • Formycon Investigative Site
    Adana, Turkey (Türkiye)
  • Formycon Investigative Site
    Diyarbakır, Turkey (Türkiye)
  • Formycon Investigative Site
    Istanbul, Turkey (Türkiye)
  • Formycon Investigative Site
    Izmir, Turkey (Türkiye)
  • Formycon Investigative Site
    Samsun, Turkey (Türkiye)
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Oct 2024 to primary completion in May 2025, 7 months.

How these figures are worked out, and which studies are left out of them.

Registered
Oct 13, 2024
First posted
Oct 16, 2024
StartActual
Oct 3, 2024
Primary completionActual
May 13, 2025
CompletionActual
May 13, 2025
Last update
Jun 26, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 26, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06643117
Lead sponsor
Formycon AG
Responsible party
Sponsor
First posted
Oct 16, 2024
Start date
Oct 3, 2024
Primary completion
May 13, 2025
Completion
May 13, 2025
Last update
Jun 26, 2025

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is terminated, as verified in Jun 2025. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion